Drugs / JX09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06183671 | Jan → Dec 2024 | resistant hypertension | Ji Xing Pharmaceuticals Australia Pty Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JX09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06183671 ↗ |
| Route | Oral | “JX09 in capsule will be administered as a two single oral doses” NCT06183671 ↗ |